MEDBOT-B (MicroPort MedBot-B) soared 6.32% intraday on Monday, reflecting strong investor sentiment following the company's latest financial disclosures.
The surge comes after the company recently disclosed its annual results, reporting revenue of approximately 551 million RMB, representing a year-over-year increase of over 114%. Gross profit surged significantly, and the pre-tax loss narrowed by more than 60%, indicating improved operational efficiency and financial health.
Core products including the Toumai laparoscopic surgical robot, Honghu orthopedic surgical robot, and Dragonfly Eye electronic laparoscope continued to advance commercial installations. Overseas market expansion also accelerated, reflecting the company's progressively materializing commercialization capabilities as its robotic surgery platform scales.
Comments